Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective

Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishnan, Sharanya, Kumar, Jeevan, Datta, Suvro Sankha, Radhakrishnan, Vivek, Nair, Reena, Chandy, Mammen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/
https://www.ncbi.nlm.nih.gov/pubmed/36531042
http://dx.doi.org/10.3389/fonc.2022.1062296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/
https://www.ncbi.nlm.nih.gov/pubmed/36531042
http://dx.doi.org/10.3389/fonc.2022.1062296

Ejemplares similares